Epigenetically regulated tumor-associated antigens in melanoma

Expert Review of Dermatology

Volumn 4, Issue 2, 2009, Pages 145-154

  Nicolay, Hugues J M ^a,b   Sigalotti, Luca ^b   Fonsatti, Ester ^a   Covre, Alessia ^a,b   Parisi, Giulia ^b   Fratta, Elisabetta ^a,b   Coral, Sandra ^b   Maio, Michele ^a,b  

^a UNIVERSITY HOSPITAL OF SIENA   (Italy)

^b CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

Cancer testis antigen; DNA methylation; Epigenetics; Histone acetylation; Immune escape; Melanoma

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; CANCER TESTIS ANTIGEN; DNA METHYLTRANSFERASE; HIGH MOLECULAR WEIGHT MELANOMA ASSOCIATED ANTIGEN; HISTONE DEACETYLASE; HISTONE METHYLTRANSFERASE; INTERLEUKIN 2; MELANOMA ANTIGEN; NY ESO 1 ANTIGEN; PROTEOCHONDROITIN SULFATE; TRICHOSTATIN A; TUMOR ANTIGEN; UNCLASSIFIED DRUG; VORINOSTAT;

ACUTE GRANULOCYTIC LEUKEMIA; BREAST CARCINOMA; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CELL ADHESION; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COLON CARCINOMA; CUTANEOUS MELANOMA; CUTANEOUS T CELL LYMPHOMA; DNA METHYLATION; DOWN REGULATION; DRUG MEGADOSE; EPIGENETICS; GENE EXPRESSION; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNOMODULATION; KIDNEY CARCINOMA; LOW DRUG DOSE; LUNG CARCINOMA; MELANOMA; MESOTHELIOMA; MYELODYSPLASTIC SYNDROME; NONHUMAN; PRIMARY EFFUSION LYMPHOMA; PRIORITY JOURNAL; PROTEIN PROCESSING; REVIEW; SARCOMA; TRANSCRIPTION REGULATION; UPREGULATION;

EID: 69949178318     PISSN: 17469872     EISSN: None     Source Type: Journal    
DOI: 10.1586/edm.09.6     Document Type: Review

References (106)

1. Renkvist N, Castelli C, Robbins PF, Parmiani G. A listing of human tumor antigens recognized by T cells. Cancer Immunol. Immunother. 50(1), 3-15 (2001).
2. van der Bruggen P, Van den Eynde BJV. Processing and presentation of tumor antigens and vaccination strategies. Curr. Opin. Immunol. 18(1), 98-104 (2006).
3. Scanlan MJ, Simpson AJ, Old LJ. The cancer/testis genes: review, standardization, and commentary. Cancer Immunol. 4, 1 (2004).
4. van der Bruggen P, Traversari C, Chomez P et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254(5038), 1643-1647 (1991).
5. Kawakami Y, Eliyahu S, Delgado CH et al. Identi?cation of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc. Natl Acad. Sci. USA 91(14), 6458-6462 (1994).
6. Gnjatic S, Nishikawa H, Jungbluth AA et al. NY-ESO-1: review of an immunogenic tumor antigen. In: Advances in Cancer Research. George FV (Eds). Elsevier, Academic Press, MA, USA 1-30 (2006)
7. Scanlan MJ, Gout I, Gordon CM et al. Humoral immunity to human breast cancer: antigen definition and quantitative analysis of mRNA expression. Cancer Immunol. 1, 4 (2001).
8. Kirkwood JM, Tarhini AA, Panelli MC et al. Next generation of immunotherapy for melanoma. J. Clin. Oncol. 26(20), 3445-3455 (2008).
9. Demierre MF, Sabel MS, Margolin KA, Daud AI, Sondak VK. State of the science 60th anniversary review: 60 years of advances in cutaneous melanoma epidemiology, diagnosis, and treatment, as reported in the journal Cancer. Cancer 113(7 Suppl.), 1728-1743 (2008).
10. Boon T, Coulie PG, Van den Eynde BJV, van der Bruggen P. Human T cell responses against melanoma. Annu. Rev. Immunol. 24(1), 175-208 (2006).
11. Rosenberg SA. Progress in human tumour immunology and immunotherapy. Nature 411(6835), 380-384 (2001).
12. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat. Med. 10(9), 909-915 (2004).
13. Terando AM, Faries MB, Morton DL. Vaccine therapy for melanoma: current status and future directions. Vaccine 25(Suppl. 2), B4-B16 (2007).
14. Durrant LG, Scholefield JH. Principles of cancer treatment by immunotherapy. Surgery (Oxford) 24(2), 55-58 (2006).
15. Mocellin S, Rossi CR, Nitti D. Cancer vaccine development: on the way to break immune tolerance to malignant cells. Exp. Cell Res. 299(2), 267-278 (2004).
16. Garcia-Lora A, Algarra I, Garrido F. MHC class I antigens, immune surveillance, and tumor immune escape. J. Cell. Physiol. 195(3), 346-355 (2003).
17. Seliger B, Cabrera T, Garrido F, Ferrone S. HLA class I antigen abnormalities and immune escape by malignant cells. Semin. Cancer Biol. 12(1), 3-13 (2002).
18. Aptsiauri N, Cabrera T, Garcia-Lora A, Lopez-Nevot MA, Ruiz-Cabello F, Garrido F. MHC class I antigens and immune surveillance in transformed cells. In: International Review of Cytology A Survey of Cell Biology. Kwang WJ (Ed.). Academic Press, MA, USA 139-189 (2007).
19. Chang CC, Campoli M, Ferrone S. HLA class I defects in malignant lesions: what have we learned? Keio J. Med. 52(4), 220-229 (2003).
20. De Smet C, Loriot A, Boon T. Promoter-dependent mechanism leading to selective hypomethylation within the 5′ region of gene MAGE-A1 in tumor cells. Mol. Cell. Biol. 24(11), 4781-4790 (2004).
21. Arnold JM, Cummings M, Purdie D, Chenevix-Trench G. Reduced expression of intercellular adhesion molecule-1 in ovarian adenocarcinomas. Br. J. Cancer 85(9), 1351-1358 (2001).
22. Hellebrekers DM, Castermans K, Vire E et al. Epigenetic regulation of tumor endothelial cell anergy: silencing of intercellular adhesion molecule-1 by histone modifications. Cancer Res. 66(22), 10770-10777 (2006).
23. Campoli M, Ferrone S. HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance. Oncogene 27(45), 5869-5885 (2008).
24. Fonsatti E, Sigalotti L, Coral S, Colizzi F, Altomonte M, Maio M. Methylation-regulated expression of HLA class I antigens in melanoma. Int. J. Cancer 105(3), 430-431 (2003).
25. Serrano A, Tanzarella S, Lionello I et al. Rexpression of HLA class I antigens and restoration of antigen-specific CTL response in melanoma cells following 5-aza-2′-deoxycytidine treatment. Int. J. Cancer 94(2), 243-251 (2001).
26. Coral S, Sigalotti L, Gasparollo A et al. Prolonged upregulation of the expression of HLA class I antigens and costimulatory molecules on melanoma cells treated with 5-aza-2′-deoxycytidine (5-AZA-CdR). J. Immunother. 22(1), 16-24 (1999).
27. Magner WJ, Kazim AL, Stewart C et al. Activation of MHC class I, II, and CD40 gene expression by histone deacetylase inhibitors. J. Immunol. 165(12), 7017-7024 (2000).
28. Maio M, Coral S, Fratta E, Altomonte M, Sigalotti L. Epigenetic targets for immune intervention in human malignancies. Oncogene 22(42), 6484-6488 (2003).
29. James SR, Link PA, Karpf AR. Epigenetic regulation of X-linked cancer/ germline antigen genes by DNMT1 and DNMT3b. Oncogene 25(52), 6975-6985 (2006).
30. Baylin SB. DNA methylation and gene silencing in cancer. Nat. Clin. Pract. Oncol. 2(Suppl. 1), S4-S11 (2005).
31. Baylin SB, Ohm JE. Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction? Nat. Rev. Cancer 6(2), 107-116 (2006).
32. Gronbaek K, Hother C, Jones PA. Epigenetic changes in cancer. APMIS 115(10), 1039-1059 (2007).
33. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat. Rev. Genet. 3(6), 415-428 (2002).
34. Jones PA, Baylin SB. The epigenomics of cancer. Cell 128(4), 683-692 (2007).
35. Smith LT, Otterson GA, Plass C. Unraveling the epigenetic code of cancer for therapy. Trends Genet. 23(9), 449-456 (2007).
36. Ting AH, McGarvey KM, Baylin SB. The cancer epigenome - components and functional correlates. Genes Dev. 20(23), 3215-3231 (2006).
37. Tomasi TB, Magner WJ, Khan AN. Epigenetic regulation of immune escape genes in cancer. Cancer Immunol. Immunother. 55(10), 1159-1184 (2006).
38. Sigalotti L, Fratta E, Coral S et al. Intratumor heterogeneity of cancer/testis antigens expression in human cutaneous melanoma is methylation-regulated and functionally reverted by 5-aza-2′-deoxycytidine. Cancer Res. 64(24), 9167-9171 (2004).
39. Sigalotti L, Coral S, Fratta E et al. Epigenetic modulation of solid tumors as a novel approach for cancer immunotherapy. Semin. Oncol. 32(5), 473-478 (2005).
40. Coral S, Sigalotti L, Colizzi F et al. Phenotypic and functional changes of human melanoma xenografts induced by DNA hypomethylation: immunotherapeutic implications. J. Cell. Physiol. 207(1), 58-66 (2006).
41. Sigalotti L, Coral S, Nardi G et al. Promoter methylation controls the expression of MAGE2, 3 and 4 genes in human cutaneous melanoma. J. Immunother. 25(1), 16-26 (2002).
42. Sigalotti L, Coral S, Altomonte M et al. Cancer testis antigens expression in mesothelioma: role of DNA methylation and bioimmunotherapeutic implications. Br. J. Cancer 86(6), 979-982 (2002).
43. Coral S, Sigalotti L, Altomonte M et al. 5-aza-2′-deoxycytidine-induced expression of functional cancer testis antigens in human renal cell carcinoma: immunotherapeutic implications. Clin. Cancer Res. 8(8), 2690-2695 (2002).
44. Fonsatti E, Nicolay HJ, Sigalotti L et al. Functional up-regulation of human leukocyte antigen class I antigens expression by 5-aza-2′-deoxycytidine in cutaneous melanoma: immunotherapeutic implications. Clin. Cancer Res. 13(11), 3333-3338 (2007).
45. Antequera F, Bird A. CpG islands as genomic footprints of promoters that are associated with replication origins. Curr. Biol. 9(17), R661-R667 (1999).
46. Bird A. Perceptions of epigenetics. Nature 447(7143), 396-398 (2007).
47. Sigalotti L, Fratta E, Coral S et al. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications. J. Cell. Physiol. 212(2), 330-344 (2007).
48. Patino WD, Susa J. Epigenetics of cutaneous melanoma. Adv. Dermatol. 24, 59-70 (2008).
49. Hellebrekers DM, Griffioen AW, van Engeland M. Dual targeting of epigenetic therapy in cancer. Biochim. Biophys. Acta 1775(1), 76-91 (2007).
50. Robertson KD, Uzvolgyi E, Liang G et al. The human DNA methyltransferases (DNMTs) 1, 3a and 3b: coordinate mRNA expression in normal tissues and overexpression in tumors. Nucleic Acids Res. 27(11), 2291-2298 (1999).
51. Klose RJ, Bird AP. Genomic DNA methylation: the mark and its mediators. Trends Biochem. Sci. 31(2), 89-97 (2006).
52. Nephew KP, Huang TH. Epigenetic gene silencing in cancer initiation and progression. Cancer Lett. 190(2), 125-133 (2003).
53. Marks PA, Breslow R. Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat. Biotechnol. 25(1), 84-90 (2007).
54. Liang G, Lin JC, Wei V et al. Distinct localization of histone H3 acetylation and H3-K4 methylation to the transcription start sites in the human genome. Proc. Natl Acad. Sci. USA 101(19), 7357-7362 (2004).
55. Margueron R, Trojer P, Reinberg D. The key to development: interpreting the histone code? Curr. Opin. Genet. Dev. 15(2), 163-176 (2005).
56. Schubeler D, MacAlpine DM, Scalzo D et al. The histone modification pattern of active genes revealed through genome-wide chromatin ana lysis of a higher eukaryote. Genes Dev. 18(11), 1263-1271 (2004).
57. Lund AH, van Lohuizen M. Epigenetics and cancer. Genes Dev. 18(19), 2315-2335 (2004).
58. Feizi T. Demonstration by monoclonal antibodies that carbohydrate structures of glycoproteins and glycolipids are onco-developmental antigens. Nature 314(6006), 53-57 (1985).
59. Jotti GS, Bombardieri E. Circulating tumor markers in breast cancer (review). Anticancer Res. 10(1), 253-258 (1990).
60. Li G, Miles A, Line A, Rees RC. Identification of tumour antigens by serological ana lysis of cDNA expression cloning. Cancer Immunol. Immunother. 53(3), 139-143 (2004).
61. Campoli MR, Chang CC, Kageshita T, Wang X, McCarthy JB, Ferrone S. Human high molecular weight-melanoma-associated antigen (HMW-MAA): a melanoma cell surface chondroitin sulfate proteoglycan (MSCP) with biological and clinical significance. Crit. Rev. Immunol. 24(4), 267-296 (2004).
62. Mittelman A, Chen GZ, Wong GY, Liu C, Hirai S, Ferrone S. Human high molecular weight-melanoma associated antigen mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: modulation of the immunogenicity in patients with malignant melanoma. Clin. Cancer Res. 1(7), 705-713 (1995).
63. Luo W, Wang X, Kageshita T, Wakasugi S, Karpf AR, Ferrone S. Regulation of high molecular weight-melanoma associated antigen (HMW-MAA) gene expression by promoter DNA methylation in human melanoma cells. Oncogene 25(20), 2873-2884 (2006).
64. Simpson AJ, Caballero OL, Jungbluth A, Chen YT, Old LJ. Cancer/testis antigens, gametogenesis and cancer. Nat. Rev. Cancer 5(8), 615-625 (2005).
65. Jager E, Stockert E, Zidianakis Z et al. Humoral immune responses of cancer patients against "Cancer-Testis" antigen NY-ESO-1: correlation with clinical events. Int. J. Cancer 84(5), 506-510 (1999).
66. Stockert E, Jager E, Chen YT et al. A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J. Exp. Med. 187(8), 1349-1354 (1998).
67. Jager E, Chen YT, Drijfhout JW et al. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J. Exp. Med. 187(2), 265-270 (1998).
68. Scanlan MJ, Gure AO, Jungbluth AA, Old LJ, Chen YT. Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol. Rev. 188, 22-32 (2002).
69. Zendman AJ, Ruiter DJ, van Muijen GN. Cancer/testis-associated genes: identification, expression profile, and putative function. J. Cell. Physiol. 194(3), 272-288 (2003).
70. Calabro L, Fonsatti E, Altomonte M et al. Methylation-regulated expression of cancer testis antigens in primary effusion lymphoma: immunotherapeutic implications. J. Cell. Physiol. 202(2), 474-477 (2005).
71. Gattei V, Fonsatti E, Sigalotti L et al. Epigenetic immunomodulation of hematopoietic malignancies. Semin. Oncol. 32(5), 503-510 (2005).
72. dos Santos NR, Torensma R, de Vries TJ et al. Heterogeneous expression of the SSX cancer/testis antigens in human melanoma lesions and cell lines. Cancer Res. 60(6), 1654-1662 (2000).
73. Jungbluth AA, Stockert E, Chen YT et al. Monoclonal antibody MA454 reveals a heterogeneous expression pattern of MAGE-1 antigen in formalin-fixed paraffin embedded lung tumours. Br. J. Cancer 83(4), 493-497 (2000).
74. Jungbluth AA, Chen YT, Stockert E et al. Immunohistochemical ana lysis of NY-ESO-1 antigen expression in normal and malignant human tissues. Int. J. Cancer 92(6), 856-860 (2001).
75. De Smet C, De Backer O, Faraoni I, Lurquin C, Brasseur F, Boon T. The activation of human gene MAGE-1 in tumor cells is correlated with genome-wide demethylation. Proc. Natl Acad. Sci. USA 93(14), 7149-7153 (1996).
76. Honda T, Tamura G, Waki T et al. Demethylation of MAGE promoters during gastric cancer progression. Br. J. Cancer 90(4), 838-843 (2004).
77. De Smet C, Courtois SJ, Faraoni I et al. Involvement of two Ets binding sites in the transcriptional activation of the MAGE1 gene. Immunogenetics 42(4), 282-290 (1995).
78. Sigalotti L, Covre A, Zabierowski S et al. Cancer testis antigens in human melanoma stem cells: expression, distribution, and methylation status. J. Cell. Physiol. 215(2), 287-291 (2008).
79. Roman-Gomez J, Jimenez-Velasco A, Agirre X et al. Epigenetic regulation of human cancer/testis antigen gene, HAGE, in chronic myeloid leukemia. Haematologica 92(2), 153-162 (2007).
80. Roman-Gomez J, Jimenez-Velasco A, Agirre X et al. Epigenetic regulation of PRAME gene in chronic myeloid leukemia. Leuk. Res. 31(11), 1521-1528 (2007).
81. Coral S, Sigalotti L, Covre A, Nicolay HJ, Natali PG, Maio M. 5-aza-2′ deoxycytidine in cancer immunotherapy: a mouse to man story. Cancer Res. 67(6), 2900-2901 (2007).
82. Schrump DS, Nguyen DM. Targeting the epigenome for the treatment and prevention of lung cancer. Semin. Oncol. 32(5), 488-502 (2005).
83. Weiser TS, Guo ZS, Ohnmacht GA et al. Sequential 5-aza-2 deoxycytidine-depsipeptide FR901228 treatment induces apoptosis preferentially in cancer cells and facilitates their recognition by cytolytic T lymphocytes specific for NY-ESO-1. J. Immunother. 24(2), 151-161 (2001).
84. Weiser TS, Ohnmacht GA, Guo ZS et al. Induction of MAGE-3 expression in lung and esophageal cancer cells. Ann. Thorac. Surg. 71(1), 295-301 (2001).
85. Wischnewski F, Pantel K, Schwarzenbach H. Promoter demethylation and histone ace tyl ation mediate gene expression of MAGE- A1, -A2, -A3, and -A12 in human cancer cells. Mol. Cancer Res. 4(5), 339-349 (2006).
86. Weber J, Salgaller M, Samid D et al. Expression of the MAGE-1 tumor antigen is up-regulated by the demethylating agent 5-aza-2′-deoxycytidine. Cancer Res. 54(7), 1766-1771 (1994).
87. Pellicciotta I, Cortez-Gonzalez X, Sasik R et al. Presentation of telomerase reverse transcriptase, a self-tumor antigen, is down-regulated by histone deacetylase inhibition. Cancer Res. 68(19), 8085-8093 (2008).
88. Altomonte M, Fonsatti E, Visintin A, Maio M. Targeted therapy of solid malignancies via HLA class II antigens: a new biotherapeutic approach? Oncogene 22(42), 6564-6569 (2003).
89. Chou SD, Khan AN, Magner WJ, Tomasi TB. Histone acetylation regulates the cell type specific CIITA promoters, MHC class II expression and antigen presentation in tumor cells. Int. Immunol. 17(11), 1483-1494 (2005).
90. Guo ZS, Hong JA, Irvine KR et al. De novo induction of a cancer/ testis antigen by 5-aza-2′-deoxycytidine augments adoptive immunotherapy in a murine tumor model. Cancer Res. 66(2), 1105-1113 (2006).
91. Khan AN, Magner W, Tomasi T. An epigenetic vaccine model active in the prevention and treatment of melanoma. J. Trans. Med. 5(1), 64 (2007).
92. Plimack ER, Kantarjian HM, Issa JP. Decitabine and its role in the treatment of hematopoietic malignancies. Leuk. Lymphoma 48(8), 1472-1481 (2007).
93. Issa JP, Garcia-Manero G, Giles FJ et al. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignancies. Blood 103(5), 1635-1640 (2004).
94. Kantarjian H, Oki Y, Garcia-Manero G et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 109(1), 52-57 (2007).
95. Oki Y, Jelinek J, Shen L, Kantarjian HM, Issa JP. Induction of hypomethylation and molecular response after decitabine therapy in patients with chronic myelomonocytic leukemia. Blood 111(4), 2382-2384 (2008).
96. Kantarjian HM, O'brien S, Cortes J et al. Results of decitabine (5-aza-2′deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia. Cancer 98(3), 522-528 (2003).
97. Wijermans P, Lubbert M, Verhoef G et al. Low-dose 5-aza-2′-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter Phase II study in elderly patients. J. Clin. Oncol. 18(5), 956-962 (2000).
98. Momparler RL, Momparler LF, Samson J. Combinational chemotherapy of L1210 and L1210/ARA-C leukemia with 5-aza-2′-deoxycytidine and b-2′-deoxythioguanosine. Int. J. Cancer 30(3), 361-364 (1982).
99. Yang AS, Doshi KD, Choi SW et al. DNA methylation changes after 5-aza-2′-deoxy-cytidine therapy in patients with leukemia. Cancer Res. 66(10), 5495-5503 (2006).
100. Sigalotti L, Altomonte M, Colizzi F et al. 5-aza-2′-deoxycytidine (decitabine) treatment of hematopoietic malignancies: a multimechanism therapeutic approach? Blood 101(11), 4644-4646 (2003).
101. Aparicio A, Eads CA, Leong LA et al. Phase I trial of continuous infusion 5-aza-2′-deoxycytidine. Cancer Chemother. Pharmacol. 51(3), 231-239 (2003).
102. Samlowski WE, Leachman SA, Wade M et al. Evaluation of a 7-day continuous intravenous infusion of decitabine: inhibition of promoter-specific and global genomic DNA methylation. J. Clin. Oncol. 23(17), 3897-3905 (2005).
103. Schrump DS, Fischette MR, Nguyen DM et al. Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura. Clin. Cancer Res. 12(19), 5777-5785 (2006).
104. Gollob JA, Sciambi CJ, Peterson BL et al. Phase I trial of sequential low-dose 5-aza-2′-deoxycytidine plus high-dose intravenous bolus interleukin-2 in patients with melanoma or renal cell carcinoma. Clin. Cancer Res. 12(15), 4619-4627 (2006).
105. Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat. Rev. Cancer 6(1), 38-51 (2006).
106. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat. Rev. Drug Discov. 5(9), 769-784 (2006).